Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 3/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25496027 | 1.00 | AHCY (0.59) | AHCYADORA3ADORA2B | |
| SCHEMBL17325435 | 0.91 | ADORA3 (0.58) | AHCYADORA3ADORA2B | |
| SCHEMBL25496028 | 0.91 | ADORA3 (0.58) | AHCYADORA3ADORA2B | |
| SCHEMBL26230981 | 0.87 | AHCY (0.56) | AHCYADORA3 | |
| SCHEMBL26327166 | 0.86 | AHCY (0.43) | AHCY | |
| SCHEMBL25496037 | 0.86 | AHCY (0.43) | AHCY | |
| SCHEMBL26298194 | 0.85 | P2RY1 (0.44) | — | |
| SCHEMBL25496133 | 0.85 | PRMT5 (0.47) | AHCY | |
| SCHEMBL25495952 | 0.85 | PRMT5 (0.47) | AHCY | |
| SCHEMBL26533849 | 0.84 | P2RY12 (0.40) | AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | AHCY 1261/4885ADORA3 1201/4885ADORA2B 1812/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | AHCY 4633/4885ADORA3 378/4885ADORA2B 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.